Evidence map›Paper›PMID 39037766›Full record

ArticleCancer research2024

Scribble Deficiency Promotes Pancreatic Ductal Adenocarcinoma Development and Metastasis.

Camino Bermejo-Rodriguez, Joaquín Araos Henríquez, Giuseppina Caligiuri, Sara Pinto Teles, Youngkyu Park, Anthony Evans, Lawrence N Barrera, Albrecht Neesse, Robert Grützmann, Daniela Aust and 12 more

Abstract read
In one paragraph

Article in Cancer research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors.

Camino Bermejo-RodriguezDepartment of Molecular and Clinical Cancer Medicine, University of Liverpool, Liverpool, United Kingdom.ORCID 0000-0002-7554-1640
Joaquín Araos Henríquez *Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, United Kingdom.ORCID 0000-0002-0901-7672
Giuseppina Caligiuri *Cold Spring Harbor Laboratory, New York, New York.ORCID 0000-0001-8798-8418
Sara Pinto TelesCancer Research UK Cambridge Institute, University of Cambridge, Cambridge, United Kingdom.ORCID 0000-0002-7409-9651
Youngkyu ParkCold Spring Harbor Laboratory, New York, New York.ORCID 0000-0003-1169-6739
Anthony EvansDepartment of Molecular and Clinical Cancer Medicine, University of Liverpool, Liverpool, United Kingdom.ORCID 0000-0001-8547-1730
Lawrence N BarreraDepartment of Molecular and Clinical Cancer Medicine, University of Liverpool, Liverpool, United Kingdom.ORCID 0009-0000-1908-162X
Albrecht NeesseDepartment of Gastroenterology, Gastrointestinal Oncology and Endocrinology, University Medical Centre Goettingen, Goettingen, Germany.ORCID 0000-0002-3690-1957
Robert GrützmannDepartment of Surgery, Universitätsklinikum Erlangen, Erlangen, Germany.ORCID 0000-0003-2559-0476
Daniela AustInstitute for Pathology, University Hospital Carl Gustav Carus, Dresden, Germany.ORCID 0000-0002-4867-8852
Petra RümmeleInstitute of Pathology, Universitätsklinikum Erlangen, Erlangen, Germany.ORCID 0000-0001-6909-9545
Thomas KnöselInstitute of Pathology, Ludwig-Maximilians-Universität (LMU) Munich, Munich, Germany.ORCID 0000-0002-1822-0197
Masako NaritaCancer Research UK Cambridge Institute, University of Cambridge, Cambridge, United Kingdom.ORCID 0000-0002-9774-4908
Masashi NaritaCancer Research UK Cambridge Institute, University of Cambridge, Cambridge, United Kingdom.ORCID 0000-0001-7764-577X
Fiona CampbellDepartment of Pathology, Royal Liverpool University Hospital, Liverpool, United Kingdom.ORCID 0009-0006-3189-1127
Daniel ÖhlundDepartment of Radiation Sciences, Umeå University, Umeå, Sweden.ORCID 0000-0002-5847-2778
Christian PilarskyDepartment of Surgery, Uniklinikum Erlangen, Friedrich-Alexander Universität Erlangen-Nürnberg (FAU), Erlangen, Germany.ORCID 0000-0002-7968-3283
Lukas E DowDepartment of Biochemistry, Weill Cornell Medicine, New York, New York.ORCID 0000-0001-7048-1418
Patrick O HumbertDepartment of Biochemistry and Chemistry, La Trobe Institute for Molecular Science, La Trobe University, Victoria, Australia.ORCID 0000-0002-1366-6691
Giulia BiffiCancer Research UK Cambridge Institute, University of Cambridge, Cambridge, United Kingdom.ORCID 0000-0003-4592-0970
David A TuvesonCold Spring Harbor Laboratory, New York, New York.ORCID 0000-0002-8017-2712
Pedro A Perez-ManceraDepartment of Molecular and Clinical Cancer Medicine, University of Liverpool, Liverpool, United Kingdom.ORCID 0000-0002-4483-5136

Funding

Single-Cell Biology Shared ResourceP30CA045508 · NCI · COLD SPRING HARBOR LABORATORY · PI David A Tuveson · 1987 to 2026
$118.9M
Pancreatic Cancer Detection ConsortiumU01CA210240 · NCI · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI Michael A. Hollingsworth · 2017 to 2026
$12.9M
CSHL-JAX Patient-Derived Models of Pancreatic Cancer as Systems for Investigating Tumor HeterogeneityU01CA224013 · NCI · COLD SPRING HARBOR LABORATORY · PI ROBSON, PAUL, TUVESON, DAVID A · 2018 to 2022
$4.2M
Fibroblast Heterogeneity in Pancreatic CancerR01CA249002 · NCI · COLD SPRING HARBOR LABORATORY · PI TUVESON, DAVID A · 2021 to 2025
$3.9M
Nrf2 Regulation of Ductal Pancreatic Cancer Etiology and Treatment ResponseR01CA188134 · NCI · COLD SPRING HARBOR LABORATORY · PI TUVESON, DAVID A · 2017 to 2021
$3.0M
Preclinical Models for Cancer Therapeutic DevelopmentR50CA211506 · NCI · COLD SPRING HARBOR LABORATORY · PI PARK, YOUNGKYU · 2016 to 2025
$2.1M
TOBACCO FLAVOR COMPOUNDSP01CA029580 · NCI · INSTITUTE FOR CANCER PREVENTION · PI HOFFMAN, DIETRICH K · 1985 to 1995
–
American Cancer Research FoundationCambridge Trust/University of CambridgeCancer Research UK Cambridge Institute, University of Cambridge (CRUK CI)Cancer Research UK Cambridge Institute, University of Cambridge (CRUK CI) C9545/A29580Cancer Research UK (CRUK) A27463Deutsche Krebshilfe (German Cancer Aid) 70113213National Cancer Institute (NCI) R50CA211506National Centre for the Replacement Refinement and Reduction of Animals in Research (NC3Rs) NC/V001167/1National Institutes of Health (NIH) 5P30CA45508NCI NIH HHS P30 CA045508NCI NIH HHS R01 CA188134NCI NIH HHS R01 CA249002NCI NIH HHS R50 CA211506NCI NIH HHS U01 CA210240NCI NIH HHS U01 CA224013Pancreatic Cancer Research FoundationRoyal Society (The Royal Society)The Hampson Legacy Trust A0873/CFUniversity of Liverpool (UoL)Wellcome Isaac ISSF/University of CambridgeWellcome Trust
6 · The paper itself

Abstract

Perturbation of cell polarity is a hallmark of pancreatic ductal adenocarcinoma (PDAC) progression. Scribble (SCRIB) is a well-characterized polarity regulator that has diverse roles in the pathogenesis of human neoplasms. To investigate the impact of SCRIB deficiency in PDAC development and progression, Scrib expression was genetically ablated in well-established mouse models of PDAC. Scrib loss in combination with KrasG12D did not influence development of pancreatic intraepithelial neoplasms in mice. However, Scrib deletion cooperated with KrasG12D and concomitant Trp53 heterozygous deletion to promote invasive PDAC and metastatic dissemination, leading to reduced overall survival. Immunohistochemical and transcriptome analyses revealed that Scrib-null tumors display a pronounced reduction of collagen content and an abundance of cancer-associated fibroblasts (CAF). Mechanistically, IL1α levels were reduced in Scrib-deficient tumors, and Scrib knockdown downregulated IL1α in mouse PDAC organoids (mPDO), which impaired CAF activation. Furthermore, Scrib loss increased YAP activation in mPDOs and established PDAC cell lines, enhancing cell survival. Clinically, SCRIB expression was decreased in human PDAC, and SCRIB mislocalization was associated with poorer patient outcome. These results indicate that SCRIB deficiency enhances cancer cell survival and remodels the tumor microenvironment to accelerate PDAC development and progression, establishing the tumor suppressor function of SCRIB in advanced pancreatic cancer.  Significance: SCRIB loss promotes invasive pancreatic cancer development via both cell-autonomous and non-cell-autonomous processes and is associated with poorer outcomes, denoting SCRIB as a tumor suppressor and potential biomarker for the prediction of recurrence.

Indexed as

Carcinoma, Pancreatic DuctalPancreatic NeoplasmsTumor Suppressor ProteinsAnimalsCancer-Associated FibroblastsCell Line, TumorGene Expression Regulation, NeoplasticHumansInterleukin-1alphaIntracellular Signaling Peptides and ProteinsMembrane ProteinsMiceMice, KnockoutNeoplasm MetastasisOrganoidsProto-Oncogene Proteins p21(ras)Hras protein, mouseInterleukin-1alphaIntracellular Signaling Peptides and ProteinsMembrane ProteinsProto-Oncogene Proteins p21(ras)SCRIB protein, humanscrib protein, mouseTrp53 protein, mouseTumor Suppressor Protein p53Tumor Suppressor Proteins

Identifiers

PMID39037766
PMCPMC12662065

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.